Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
Launched by UNIVERSITY HOSPITAL, ALEXANDROUPOLIS · Apr 14, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a new eye treatment called Faricimab on kidney function in people with diabetes. Faricimab is an injection used to treat eye conditions like diabetic macular edema (swelling in the eye due to diabetes) and age-related macular degeneration. Previous treatments have sometimes caused kidney problems, so this study is important to see if Faricimab, which targets certain harmful proteins, might help protect kidney function instead, especially in diabetic patients who already have some kidney issues.
To be eligible for this trial, participants must have diabetes and either diabetic macular edema, age-related macular degeneration, or swelling in the eye from a blocked vein. They should also be taking medications that help protect their kidneys. However, individuals with severe kidney disease, those who are pregnant, or those who have had a kidney transplant or are on dialysis cannot participate. If you join the study, you can expect to receive regular check-ups and monitoring to assess both your eye condition and kidney health throughout the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with diabetes
- • Patients with DME or nAMD or macular edema secondary to retinal vein occlusion
- • Patients already receiving nephroprotective drugs
- Exclusion Criteria:
- • Patients with end stage renal disease
- • Pregnancy
- • Patients with other retinal disorders
- • Previous renal transplantation Patients under hemodialysis
About University Hospital, Alexandroupolis
University Hospital Alexandroupolis is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. As a prominent institution in the region, the hospital integrates cutting-edge medical practices with comprehensive patient care, fostering an environment that promotes scientific inquiry and collaboration. With a focus on enhancing treatment options and improving patient outcomes, the hospital conducts a diverse range of clinical trials across various medical specialties, contributing to the development of new therapies and evidence-based practices. Its commitment to excellence in research and education positions University Hospital Alexandroupolis as a key player in the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alexandroupolis, Evros, Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported